DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for fibrochondrogenesis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFibrochondrogenesis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fibrochondrogenesis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Fibrochondrogenesis is a rare, neonatally lethal chondrodysplasia first described in 1978. The eighth published case was identified in a population of 1,158,067 consecutive livebirths in Spain, giving a minimal prevalence figure for livebirths from that series. Only 13 cases had been published by 2004. The disorder shows abnormal maturation and disturbed growth of cartilage and bones. Two sibs born to a consanguineous couple confirmed autosomal recessive inheritance.
Prenatal ultrasonography at 22 weeks in one case revealed intrauterine growth retardation, an apparently large head, hypoplasia of the thorax, a prominent abdomen, rhizomelic limbs, and wide metaphyses — the last finding reported as not seen in other lethal dysplasias. Postnatal radiographs show broad, long-bone metaphyses (dumb-bell shaped) and pear-shaped vertebral bodies. A 2012 case report gave a comprehensive pictorial review of antenatal ultrasound and postnatal radiographic findings, noting that only few cases are diagnosed before termination of pregnancy.
No treatments or interventions are described in any of these reports. The condition is uniformly lethal in the neonatal period. No molecular or genetic mechanism beyond autosomal recessive inheritance is specified in these abstracts.
What is missing: a molecular diagnosis or gene identification, any animal model, any cell or tissue bank for research, and any funding or organised effort to study the underlying biology. Without these, no drug repurposing hypothesis can be generated.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Medical Genetics · 1996 · 15 citations · open access
A new case of fibrochondrogenesis from Spain.
AbstractA rare, neonatally lethal chondrodysplasia with histological characteristics was first described in 1978 and the authors named the condition fibrochondrogenesis. Here we report the eighth published case of fibrochondrogenesis. This was identified in a population of 1,158,067 consecutive livebirths, so we can assume that this figure should be the minimal prevalence for livebirths.
American Journal of Medical Genetics Part A · 2004 · 11 citations
Two sibs with fibrochondrogenesis
AbstractFibrochondrogenesis is one of the rare lethal osteochondrodysplasias, which show abnormal maturation, and disturbed growth of cartilage and bones. These disorders are a heterogenous group of genetic disorders with a total incidence of 1-3 in 10,000 births. Only 13 cases of fibrochondrogenesis have been published since Lazzaroni-Fossati et al. [1978] first described the disorder. We report on two sibs that occurred in a consanguineous couple and discuss the ultrasonographic, clinical, radiological, and pathological characteristics of this disorder. This occurrence confirms autosomal recessive inheritance of fibrochondrogenesis.
American Journal of Perinatology · 1998 · 9 citations
Prenatal Ultrasonography: Clinical and Radiological Findings in a Boy with Fibrochondrogenesis
AbstractFibrochondrogenesis, a rare lethal chondrodysplasia has been reported on nine patients. We report on a boy with fibrochondrogenesis whose parents were second cousins. Prenatal ultrasonography performed at 22 weeks of gestation revealed an intrauterine growth retardation, an apparently large head, an hypoplasia of the thorax, a prominent abdomen, rhizomelic limbs, and wide metaphysis. The latest have never been reported in other lethal dysplasias.
Journal of Clinical Imaging Science · 2012 · 1 citations · open access
Fibrochondrogenesis, an Antenatal and Postnatal Correlation
AbstractFibrochondrogenesis is a rare, neonatally lethal osteochondrodysplasia, with autosomal recessive inheritance. It differs from other lethal dwarfisms in that it leads to broad, long-bone metaphyses (dumb-bell shaped) and pear-shaped vertebral bodies. We report a case of fibrochondrogenesis with severe pear-shaped platyspondyly, suspected antenatally, and give a comprehensive pictorial review of the antenatal ultrasound and postnatal radiographic findings. Only few cases of fibrochondrogenesis are diagnosed before the termination of pregnancy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
